Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Denali Therapeutics Inc.

NASDAQ: DNLI · Life Sciences · 2 alerts · CIK 1714899

Share price
$18.08Close, Nov 16
Market cap
$2.9B
Shares outstanding
160.29MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Denali Therapeutics Inc. filings on SEC EDGAR ↗

4:07 PM ET 10-Q
Financial Results

Denali Therapeutics Q3 2026 Results: Turns Profitable, Net Income $70.1M

Denali Therapeutics reported a net income of $70.1 million for the third quarter of 2026, driven by a $194.0 million gain from the sale of a priority review voucher. However, the company recorded a net loss of $185.9 million for the first nine months of 2026, reflecting ongoing heavy investment in research and development and the initial recognition of product revenue.

Key figure
Net income $70.1M
4:04 PM ET 8-K
Financial Results

Denali Therapeutics Financial Results

Denali Therapeutics reported Q3 2026 financial results, highlighted by $17.8 million in net product revenue for AVLAYAH and a net income of $70.1 million. The company's cash position reached $1.0 billion, bolstered by a $194.0 million net gain from the sale of a Priority Review Voucher.

Term
Q3 2026

“Families and physicians are telling us that AVLAYAH is making a difference for children with Hunter syndrome, and the results this quarter reflect that. The positive responses to AVLAYAH across patients, physicians and payers, and our team’s strong commercial execution, show what is possible for our TransportVehicle portfolio.”

Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.